ReShape Lifesciences (RSLS) announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market indicating that the Company has regained compliance with Nasdaq’s stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape announces heacount reduction, progress toward agreement completions
- ReShape Lifesciences granted key international patent in Australia
- ReShape Lifesciences Raises Equity to Avoid Delisting
- ReShape Lifesciences Closes $2.6M Stock Offering
- ReShape Lifesciences signs exclusive distribution agreement with Recon Supply